These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

885 related items for PubMed ID: 8938795

  • 1. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F, Bae I, Fornace AJ, Pommier Y.
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [Abstract] [Full Text] [Related]

  • 2. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
    Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y.
    Cancer Res; 1996 Oct 01; 56(19):4430-7. PubMed ID: 8813137
    [Abstract] [Full Text] [Related]

  • 3. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
    Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y.
    Clin Cancer Res; 1997 Sep 01; 3(9):1653-60. PubMed ID: 9815856
    [Abstract] [Full Text] [Related]

  • 4. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
    Giuliano M, Lauricella M, Vassallo E, Carabillò M, Vento R, Tesoriere G.
    Invest Ophthalmol Vis Sci; 1998 Jul 01; 39(8):1300-11. PubMed ID: 9660477
    [Abstract] [Full Text] [Related]

  • 5. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
    Debernardis D, Siré EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M.
    Cancer Res; 1997 Mar 01; 57(5):870-4. PubMed ID: 9041188
    [Abstract] [Full Text] [Related]

  • 6. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
    Sané AT, Bertrand R.
    Cancer Res; 1999 Aug 01; 59(15):3565-9. PubMed ID: 10446962
    [Abstract] [Full Text] [Related]

  • 7. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR.
    Anticancer Res; 1998 Aug 01; 18(4C):2919-32. PubMed ID: 9713486
    [Abstract] [Full Text] [Related]

  • 8. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 9. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
    Minko T, Paranjpe PV, Qiu B, Lalloo A, Won R, Stein S, Sinko PJ.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):143-50. PubMed ID: 12172980
    [Abstract] [Full Text] [Related]

  • 10. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.
    Clin Cancer Res; 2000 Apr 01; 6(4):1488-97. PubMed ID: 10778981
    [Abstract] [Full Text] [Related]

  • 11. Induction of BCL2 family member MCL1 as an early response to DNA damage.
    Zhan Q, Bieszczad CK, Bae I, Fornace AJ, Craig RW.
    Oncogene; 1997 Mar 06; 14(9):1031-9. PubMed ID: 9070651
    [Abstract] [Full Text] [Related]

  • 12. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
    Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN.
    Cancer Res; 2002 Mar 15; 62(6):1688-95. PubMed ID: 11912141
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells.
    Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, Lotan R.
    Oncogene; 1999 Apr 08; 18(14):2357-65. PubMed ID: 10327056
    [Abstract] [Full Text] [Related]

  • 14. TNF-alpha induced p21(WAF1) but not Bax in colon cancer cells WiDr with mutated p53: important role of protein stabilization.
    Kobayashi N, Takada Y, Hachiya M, Ando K, Nakajima N, Akashi M.
    Cytokine; 2000 Dec 08; 12(12):1745-54. PubMed ID: 11097743
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
    Hentze H, Latta M, Künstle G, Dhakshinamoorthy S, Ng PY, Porter AG, Wendel A.
    Hepatology; 2004 May 08; 39(5):1311-20. PubMed ID: 15122760
    [Abstract] [Full Text] [Related]

  • 16. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities.
    Schmitt E, Cimoli G, Steyaert A, Bertrand R.
    Exp Cell Res; 1998 Apr 10; 240(1):107-21. PubMed ID: 9570926
    [Abstract] [Full Text] [Related]

  • 17. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
    Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y.
    Cancer Res; 1991 Dec 01; 51(23 Pt 1):6280-5. PubMed ID: 1933888
    [Abstract] [Full Text] [Related]

  • 18. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells.
    Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordonez JV, Shroot B, Fontana JA.
    Oncogene; 1995 Aug 03; 11(3):493-504. PubMed ID: 7630633
    [Abstract] [Full Text] [Related]

  • 19. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells.
    Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y.
    Oncogene; 2001 Apr 05; 20(15):1852-9. PubMed ID: 11313933
    [Abstract] [Full Text] [Related]

  • 20. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL.
    Cancer Gene Ther; 2000 Nov 05; 7(11):1469-80. PubMed ID: 11129289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.